Andrew Mitchell is a Professor at the Faculty of Law, Monash University, and a member of the WTO Dispute Settlement Panelists Indicative List. He has extensive legal practice experience with Allens Arthur Robinson and consults for governments, international organizations, and the private sector. Mitchell has taught law in Australia, Canada, Indonesia, Singapore, and the US. He holds law degrees from the University of Melbourne, Harvard Law School, and a PhD from the University of Cambridge. His research focuses on international economic law, public international law, and digital trade governance, with a particular emphasis on the intersection of trade law and public health. Mitchell has secured six major grants, including an Australian Research Council Future Fellowship, and has authored over 170 books and articles. He serves as an editor for Edward Elgar’s International Economic Law Series and multiple journal editorial boards. Recent projects include 'Safeguarding Health in International Investment Agreements' (2022–2025) 'Maritime Cooperation for a Sustainable Indo-Pacific' (2021–2022) 'Global E-Commerce and Cottage Industries in India' (2020–2021) He has contributed to policy submissions on bilateral investment treaties and delivered lectures on data sovereignty and digital trade. His awards include editorial leadership roles at journals like the Journal of World Investment and Trade and Asia Pacific Law Review .
Azizjon ALIMOV is a Full Professor at IÉSEG School of Management (University of Lille, France), specializing in Corporate Finance, Mergers and Acquisitions, and Law and Finance. He holds a Ph.D. in Finance from the University of Oregon (2007) and an MBA from Central Michigan University (2001). His HDR (Habilitation) in Management Sciences was awarded by the University of Lille in 2023. His research focuses on corporate governance, cross-border M&A dynamics, and the interplay between legal frameworks and financial decision-making. Key themes include intellectual property rights' impact on corporate debt costs, product market competition effects on corporate cash holdings, and government borrowing influences on acquisition strategies. His work frequently examines global contexts, with studies spanning North America, Asia, and Europe. Notable publications include analyses of IPO staging mechanisms (2024), managerial discipline through trade liberalization (2023), and the role of labor protection laws in loan contracting (2015). His recent work emphasizes reproducibility in management science methodology (2023) and cross-border regulatory challenges in M&A. No scientific awards are explicitly listed; however, his extensive publication record reflects sustained academic contributions. He has advised students across institutions including City University of Hong Kong and the Sauder School of Business, though specific advisee names are not documented here. His professional experience includes roles at the University of Arizona (2008–2010), California State University (2007–2008), and as an HSBC Visiting Assistant Professor at the University of British Columbia (2016–2018). He currently leads the Finance Track at IÉSEG, contributing to programs like the Grande École Master’s in Finance and MSc Corporate Finance courses.
Ariel Pakes is the Thomas Professor of Economics at Harvard University, part of the Faculty of Arts and Sciences and the Department of Economics. He previously held the Charles and Dorothea Dilley Professorship at Yale University and tenured roles at institutions including the University of Wisconsin and the Hebrew University of Jerusalem. His research focuses on industrial organization (I.O.), the economics of technological change, and econometric theory. Pakes has advised notable students who now lead economics departments globally and has received prestigious awards including the Frisch Medal (1986) and election to the American Academy of Arts and Sciences (2002). Education: Pakes earned his Ph.D. in Economics from Harvard University in 1980. His academic journey includes roles as a lecturer at Harvard and positions at the University of Jerusalem. Research Interests: Pakes has pioneered methodologies for analyzing I.O. models, including demand and cost system estimation. Recent work examines AI’s impact on pricing strategies, antitrust policy implications of market dynamics, and healthcare cost structures. His theoretical contributions include simulation estimators and frameworks for dynamic oligopolies. Awards: Frisch Medal (Econometric Society, 1986) Fellow of the Econometric Society (1988) Fellow of the American Academy of Arts and Sciences (2002) Best Graduate Student Advisor Award (Yale University, 1996) Advisory and Grants: Pakes has served on NSF panels, including the Economics Advisory Panel and Presidential Fellow Advisory Board. His consulting work spans government agencies and large firms. He edited the RAND Journal of Economics and co-chaired the AEA Census Advisory Panel. Labs/Teams: Collaborates with NBER as a Research Associate and contributes to interdisciplinary projects like the PNAS issue on 'Science, Technology and the Economy.'
Prof. Dr. Jörg E. Drewes is a Full Professor and Chair at the Research Institute for Urban Water Management, Technical University of Munich (TUM), Germany. He also serves as Academic Program Director for Environmental Engineering at TUM and is a co-founder of Waterloop Solutions GmbH. His work spans advanced water treatment technologies, wastewater reuse, and environmental health surveillance. Affiliations : TUM, Colorado School of Mines, King Abdullah University of Science and Technology, UNSW Water Research Centre Research focuses on advanced oxidation processes , membrane fouling mitigation , micropollutant removal , and wastewater epidemiology for public health. His team develops integrated systems for water-energy-food nexus applications and graphene oxide-based treatment solutions. Recent publications address PFAS remediation , UVC-LED pre-treatment for biofouling control, and GIS-based wastewater surveillance models . Awards include the Bayerische Staatsmedaille (2023) and William Dunbar Medal (2022). 2023 : Bayerische Staatsmedaille 2022 : William Dunbar Medal 2018 : IWA Fellow He leads the Nexus@TUM initiative and contributes to EU water resilience strategies. Collaborations include projects in Germany, China, India, and Spain, focusing on climate-resilient water systems and resource recovery .
Daniel Finley is a Professor of Cell Biology at Harvard Medical School (HMS), leading the Finley Lab focused on the ubiquitin-proteasome pathway and related regulatory mechanisms. He holds academic appointments within the Department of Cell Biology and sits on the Scientific Advisory Boards of Proteostasis and X-Chem Pharmaceuticals. His research investigates proteasome function, ubiquitin-like proteins, and proteostasis roles in diseases like Alzheimer’s and ALS. Dr. Finley earned his undergraduate degree in biochemistry from Harvard University and a Ph.D. in molecular biology from MIT. After postdoctoral training at MIT, he joined HMS in 1988. His lab explores topics including erythroid proteome remodeling, mitochondrial dysfunction, and neurodegenerative disease mechanisms. Key research areas include: (1) Ubiquitin-proteasome pathway regulation, (2) Proteasome structure/function, (3) Nonproteolytic roles of ubiquitination, and (4) Pathophysiological roles of proteostasis defects in diseases. His work bridges basic cell biology with translational medicine, particularly in neurodegeneration and anemia. Finley has secured NIH funding for projects like 'Regulation of Proteasome Activity' (R35GM145246) and 'Erythrocyte maturation through global proteome remodeling' (R01HL153970). Collaborations with industry and academic partners extend his impact in drug discovery and proteasome-targeted therapies. His lab’s contributions include defining ubiquitin chain editing mechanisms, identifying USP14’s role in mitophagy, and elucidating proteostasis defects in Alzheimer's models. Research tools developed include advanced cryo-EM analyses of proteasomal structures and functional assays for ubiquitin system enzymes.
Roles & Affiliations: Ikhlas Khan serves as Director of the National Center for Natural Products Research (NCNPR), Distinguished Professor, and Research Professor of Pharmacognosy at the University of Mississippi's School of Pharmacy. He also leads the FDA Program and coordinates natural products research across multiple initiatives, including the Sino-US TCM Research Center and the Center for Research of Indian Systems of Medicine (CRISM). Education: B.Sc. Chemistry (1980) - Aligarh Muslim University, India M.Sc. Organic Chemistry (1982) - Aligarh Muslim University, India Ph.D. Pharmacy (1987) - Ludwig-Maximilians-Universität, Munich Postdoctoral Studies - Swiss Federal Institute of Technology (ETH), Zurich Research Focus: Dr. Khan specializes in natural products research with emphasis on: Phytomedicine: Standardization of herbal products via analytical fingerprinting, pesticide/herbicide residue analysis, and bioanalytical quality control. Drug Discovery: Isolation of bioactive natural products, development of analytical methods for phytochemical characterization, and chiral separation techniques. Metabolism Studies: Role of metabolism in drug/natural product activity, particularly in aminoquinoline antimalarials. His work bridges academia, industry, and regulatory bodies, shaping policies for botanical supplements. Key Contributions: Over 850 peer-reviewed publications and leadership in high-impact projects like the FDA Center of Excellence. His lab pioneered methods to combat herbal product adulteration and safety issues. Awards & Recognition: UM Distinguished Professor Award (2018) Wiley Award (AOAC International, 2018) Qihuang International Prize (2017) Honoris Causa Doctorate (University of Hamdard, 2012) Labs & Collaborations: Directs the NCNPR, a global leader in natural products research, and collaborates with institutions worldwide. His team develops technologies for herbal product authentication and drug metabolism studies.
Jörg Bohlmann is a Professor in the Department of Forest and Conservation Sciences at the University of British Columbia , affiliated with the Michael Smith Laboratories, Botany Department (Faculty of Science), and Wine Research Centre. His research spans genomics, biochemistry, and chemical ecology of plant specialized metabolism, focusing on terpenoids and phenolics for applications in forest health and bioproducts. Research Streams : Plant defense against insects/pathogens, metabolic engineering of bioproducts, forest genomics, and molecular evolution of terpenoid pathways. Collaborations : National and international partnerships with academia, government, and biotech industries. Recent Publications highlight genomic insights into Western Redcedar (2023), including its low genetic diversity and adaptation mechanisms despite self-fertilization. Earlier work (2001–2022) covers conifer defense systems, Arabidopsis terpenoid pathways, cannabis flavor genetics, and mass spectrometry infrastructure. Scientific Awards include: NSERC E.W.R. Steacie Fellow (2015), Fellow of the Royal Society of Canada (2015), Feodor Lynen Postdoctoral Fellowship (1995–1998), and Distinguished University Scholar (UBC). Funding Sources : NSERC (Discovery/Strategic grants), CFI, Genome Canada/BC, provincial/federal agencies. Labs & Facilities : Michael Smith Laboratories (UBC), National Centre of Excellence, Forest Sciences Centre, and a dedicated mass spectrometry lab for metabolite analysis.
Vikramaditya G. Yadav is an Associate Professor at the University of British Columbia (UBC) in the Department of Chemical and Biological Engineering, Faculty of Applied Science. He directs the Master of Engineering Leadership (MEL) Program in Sustainable Process Engineering and leads the BioFoundry research group. Education: B.A.Sc., University of Waterloo (2007) Ph.D., Massachusetts Institute of Technology (2013) Postdoctoral Associate, Harvard University (2014) His research spans sustainable chemical manufacturing, metabolic engineering, and biotechnology. Key areas include: Designing biosynthetic enzymes for biomass valorization Developing bioremediation strategies for industrial water quality Creating innovative drug delivery systems and tissue engineering solutions Advancing synthetic biology for pharmaceutical and bioenergy applications His recent work focuses on ocular drug delivery, cannabinoid biosynthesis in E. coli, lignin-based nanoparticles for cancer therapy, and computational analysis of plant secondary metabolites. Collaborations with start-ups, industry, and medical labs drive innovation in Canada's bioeconomy. Professional Leadership: Chair, Biotechnology Division of the Chemical Institute of Canada Associate Editor, The Canadian Journal of Chemical Engineering He is affiliated with UBC's BioProducts Institute and contributes to project-based learning pedagogy.
Erik Gordon is a Clinical Assistant Professor of Entrepreneurial Studies and Area Chair at the Ross School of Business, University of Michigan. He holds degrees in economics and law, with prior roles including Associate Dean and Director of the Graduate Division of Business & Management at Johns Hopkins University, and leadership positions at the University of Florida’s Center for Technology & Science Commercialization Studies. His research focuses on entrepreneurship, venture capital, private equity, corporate governance, and FinTech. He frequently contributes to media outlets like The New York Times, Bloomberg, and Marketplace, offering insights on business trends and corporate strategy. His teaching spans advanced topics in business strategy, with a focus on real-world application and interdisciplinary approaches. Notable engagements include commentary on the pandemic’s impact on education and virtual teaching methodologies. He advises initiatives like the Wolverine Venture Fund and Zell Early-Stage Fund, emphasizing practical experience for students.
Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
Professor Shaun Larkin is a part-time academic at the School of Public Health , University of Sydney, specializing in Health Policy and Financing . He is affiliated with the Leeder Centre for Health Policy, Economics and Data and a member of the Charles Perkins Centre . With a career spanning executive roles at HCF and non-executive directorships in health startups, his work bridges academia and industry. Education : Harvard Business School alumnus with a HlthScD, MBA, MHSc, and BHA. His research focuses on health economics , health policy , and health services management , emphasizing: Translational research in healthcare financing Trends in private-public healthcare partnerships Price transparency in private health insurance Leadership in health systems Chronic disease management Quality use of medicines His publications reveal a trajectory from foundational work in: Psychiatric services data standardization (2000) Heart disease and diabetes management (2013-2015) Telehealth interventions (2017-2018) Private sector policy frameworks (2019-2020) Saudi Arabian health reforms (2022-present) Private equity in healthcare (2025) As an advisor, he currently supervises research students on topics including: Quality use of medicines in Saudi Arabia Sustainable financial models for private hospitals Patient-reported outcome measures in Australia He also contributes to the Leeder Centre and engages with global health startups as an investor and advisor.
Vadim Cherezov, the Ester Dornsife Chair in Biological Sciences and Professor at the University of Southern California (USC), leads groundbreaking research in membrane protein structure and function. Affiliated with the Bridge Institute, Department of Chemistry, and Michelson Center for Convergent Bioscience, his work focuses on GPCRs, ion channels, and transporters—critical targets for drug discovery. His team leverages advanced techniques like Lipidic Cubic Phase (LCP) and Serial Femtosecond Crystallography (SFX) at XFEL facilities to solve high-resolution structures under physiological conditions. Institutional Affiliations: Bridge Institute, USC Michelson Center, Department of Chemistry, Department of Pharmacology and Pharmaceutical Sciences. Key Collaborations: Katritch Lab, Kuhn Lab, NIH, European XFEL. His research explores the role of lipids in modulating GPCR function, addressing diseases like Alzheimer’s, diabetes, and cancer. By solving the structure of the A 2A adenosine receptor via sulfur SAD phasing at XFEL, Cherezov’s lab demonstrated de novo phasing without heavy atoms. This breakthrough enables structural studies of previously intractable membrane proteins. Scientific Awards & Grants: NIH R01 GM108635, U54 GM094618, U54 GM094599, R01 GM095583 Science Signaling Breakthroughs of the Year (2014) Cherezov mentors a dynamic team, including postdocs (e.g., Dong-Gyun Kim), graduate students (e.g., Behnaz Davoudinasab), and alumni (e.g., Benjamin Stauch at Eli Lilly, Nairie Michaelian at Genentech). His lab’s publications span Nature , Science , and Cell , with recent work on Science Advances (2025) addressing ABEL-FRET for GPCR dynamics.
Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.
Brooke Hudspeth, PharmD, is an Associate Professor and Chief Practice Officer at the University of Kentucky (UK) College of Pharmacy. She oversees community pharmacy initiatives and serves as acting President of the Kentucky Pharmacists Association (KPhA). Her roles include mentoring pharmacy students and residents as a preceptor, and leading collaborative projects with organizations like the American Pharmacists Association Foundation, Kroger Co., and the CDC. Educationally, she holds a Doctor of Pharmacy from the UK College of Pharmacy, alongside PGY1/PGY2 Community-based Pharmacy Practice Residencies from the same institution. Her research focuses on diabetes prevention, obesity, and pharmacist-driven clinical services, particularly through expanding the National Diabetes Prevention Program (NDPP) to five U.S. states via a $7.5M CDC grant. Research interests emphasize health disparities, vaccine accessibility, and optimizing pharmacist roles in self-care conditions. Notable projects include influenza point-of-care testing and pharmacy partnerships during the pandemic. Her work bridges academic innovation with real-world healthcare challenges, advocating for policy changes to enhance pharmacist payment for clinical services. Despite no explicitly listed awards, her impactful grant-funded projects reflect significant contributions to public health. She advises students and residents while leading residency expansion initiatives. Collaborations with major institutions underscore her role in advancing pharmacy practice and education nationally. Hudspeth’s lab/team is embedded within UK’s College of Pharmacy, focusing on translational research to improve patient care through pharmacist-led interventions. Future work includes expanding telehealth pharmacy services and addressing healthcare workforce shortages.
